Construction method of hepatic cyst animal model
By injecting streptozotocin in experimental animals and combining estrogen and adrenocorticosteroid treatment, an animal model of liver cyst was constructed, which solved the problem of lack of effective animal models in the prior art, and was used to study and clinical treatment of liver cysts. Important support was provided.
Patent Information
- Application Number
- CN202410998467.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
The existing technology lacks effective animal models to study simple liver cysts, resulting in no major breakthrough in the diagnosis and treatment of liver cysts.
By injecting streptozotocin into the abdominal cavity of the experimental animal and subsequently administering estrogen and adrenocorticosterone treatment, the formation of liver cysts can be induced in experimental animals, thereby constructing an animal model of liver cysts.
Successfully inducing liver cysts in long-clawed gerbils provides an animal model for studying liver cysts, laying the foundation for the diagnosis and treatment of liver cysts in clinical practice, and accelerating the formation of liver cysts through drug administration, improving research efficiency.
Smart Images

Figure CN118923613A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing a liver cyst animal model. Background Art
[0002] Liver cysts are a group of heterogeneous diseases with different etiologies, including sporadic simple liver cysts and hereditary polycystic liver diseases (PLD). Although most patients with this disease present with a benign course, some patients also experience symptoms and complications related to cyst enlargement and subsequent compression of abdominal organs, such as abdominal pain, early satiety, esophageal reflux or intracystic bleeding, infection, and even cyst rupture. In very few patients, liver function is impaired or even liver failure occurs due to excessive cyst size and number. Currently, the main treatments for this disease include conservative treatment, aspiration sclerotherapy, fenestration surgery, partial liver resection, and liver transplantation. Among them, partial liver resection and liver transplantation are the two methods with definite efficacy. However, as an invasive surgery, partial liver resection has many postoperative complications, and liver transplantation is subject to many restrictions in clinical practice. Therefore, liver cysts require other innovative and effective treatments, and exploring the molecular mechanism of liver cyst formation will help find new therapeutic targets.
[0003] Animal models are one of the foundations of disease research. The replication of animal disease models is to use artificial methods to make animals under certain pathogenic factors (physical, chemical, biological), causing a certain degree of damage to animal tissues, organs or the whole body, and some changes in morphology, structure, function, and metabolism similar to human diseases. This method is used to study the occurrence and development of human diseases, and it has important practical significance for the prevention and treatment of human diseases (including the trial of new drugs) and the systematic study of diseases. With the in-depth study of the pathogenesis of liver cysts, drug therapy and the development of new drug targets have gradually become hot topics, but there has been no major breakthrough in the diagnosis and treatment of liver cysts in clinical practice. The lack of a suitable animal model for studying liver cysts is also one of the important reasons.
[0004] At present, there are animal models for studying polycystic kidney disease in China, but there are basically no animal models for studying polycystic liver disease. As for the animal models for studying simple liver cysts, there are no reports. f / f PKD1 is a gene that is expressed in the PKD1 gene. f / f : Cre mice are born with the disease and have a short survival time. They can be used to study the pathogenesis of polycystic kidney disease, but are difficult to use in the study of therapeutic drugs. Han: SPRD rats are used in the study of polycystic kidney disease drugs and their mechanisms of action.
[0005] Streptozocin (STZ) is a glucosamine-nitrosourea with the following structural formula:
[0006]
[0007] It is a DNA alkylating agent that can enter cells alone through the GLUT2 glucose transporter protein and is toxic to the β cells of the pancreatic islets. STZ has a selective destructive effect on the pancreatic β cells of certain species of animals and can induce diabetes in many animals. Rats and mice are generally used to make animal models of type I diabetes. It can cause diabetes in dogs and monkeys, and it is permanent. The diabetic effect of STZ is species-specific. It does not cause diabetes in guinea pigs or humans. It is mainly used clinically for pancreatic islet cell carcinoma and has certain therapeutic effects on carcinoid tumors, Hodgkin's disease, colon cancer and liver cancer. STZ can induce liver tumors in rats and hamsters, but there are no reports that it can cause liver cysts.
[0008] Estrogen is a substance that promotes the development of secondary sexual characteristics and the maturation of sexual organs in female animals. It is secreted by the ovaries and placenta of female animals. Estrogen receptors are distributed in the uterus, vagina, breasts, pelvic cavity, skin, bladder, urethra, bones and brain. Therefore, estrogen has a wide range of important physiological effects. It not only promotes and maintains the physiological effects of female reproductive organs and secondary sexual characteristics, but also has a significant impact on the endocrine, cardiovascular, metabolic system, bone growth and maturation, skin, etc. Natural estrogens are mainly estradiol, estrone, and estriol; most of the estrogen drugs commonly used in clinical practice are derivatives synthesized from estradiol, such as estradiol benzoate, estradiol valerate, ethinyl estradiol, ethinyl estradiol, and estrone.
[0009] Dexamethasone sodium phosphate is an adrenal cortical hormone with the following structural formula:
[0010]
[0011] It has anti-inflammatory, anti-endotoxin, immunosuppressive, anti-shock and stress response enhancing pharmacological effects, so it is widely used in various departments to treat various diseases, such as autoimmune diseases, allergies, inflammation, asthma, and dermatological and ophthalmic diseases.
[0012] There are no reports that the above three compounds can cause liver cysts. Summary of the invention
[0013] Based on the deficiencies in the prior art, the applicant found in the study that after a single intraperitoneal injection of streptozotocin 150mg / kg-200mg / kg in long-clawed gerbils, the gerbils developed obvious abdominal distension after an average of about 20 months, and liver cysts were found after dissection. Therefore, the purpose of the present invention is to propose a method for constructing an animal model of liver cysts.
[0014] In order to achieve the above-mentioned purpose, the specific technical scheme of the present invention is as follows:
[0015] The invention provides a method for constructing a liver cyst animal model, comprising the following steps: injecting streptozotocin into the abdominal cavity of an experimental animal, and then feeding the experimental animal until a liver cyst grows out, so as to obtain the liver cyst animal model.
[0016] After a single intraperitoneal injection of streptozotocin, 10 gerbils in each of the blank group (intraperitoneal injection of buffer solution dissolved in STZ) and the model group (intraperitoneal injection of streptozotocin 150 mg / kg) developed liver cysts of varying degrees 16.5 months later, proving that STZ can indeed cause liver cysts in gerbils.
[0017] Preferably, streptozotocin is administered by intraperitoneal injection.
[0018] Preferably, the dosage of streptozotocin is 150 mg / kg-200 mg / kg, and the number of times of administration of streptozotocin is once.
[0019] Also, when constructing the model, the drug can be administered to experimental animals of any age, and the time for obvious liver cysts to appear after intraperitoneal injection of streptozotocin is 16.5 months.
[0020] When constructing an animal model of liver cysts, the experimental animal can be selected as the long-clawed gerbil.
[0021] Preferably, after the experimental animal is administered with streptozotocin, at least one of estrogen and adrenocortical hormone is administered.
[0022] Among them, the estrogen can be selected from any one of estradiol benzoate, estradiol valerate, ethinyl estradiol, ethinyl estradiol, and premaculata; the adrenocortical hormone can be selected from dexamethasone sodium phosphate. In the embodiment of the present invention, estradiol valerate and dexamethasone sodium phosphate are selected as examples.
[0023] Furthermore, after the administration of streptozotocin, at least one of estrogen and adrenocortical hormone is administered again at an interval of 3 months.
[0024] Furthermore, when administering both estrogen and cortical hormone, the two drugs can be administered in combination to achieve better effects.
[0025] The first scheme: after STZ treatment, drugs (estrogen (estradiol valerate) and adrenocortical hormone (dexamethasone sodium phosphate)) were directly administered. Samples were taken 3 months, 4 months, and 6 months after administration and it was found that long-clawed gerbils could develop a certain degree of liver cysts at different time points, indicating that the administration of drugs (estrogen (estradiol valerate) and adrenocortical hormone (dexamethasone sodium phosphate)) can accelerate the occurrence of liver cysts.
[0026] The second approach: Three months after STZ injection, long-clawed gerbils began to receive medication (estrogen (estradiol valerate) and adrenocortical hormone (dexamethasone sodium phosphate, either alone or in combination). Samples were taken 24 days, 42 days, and 3 months after medication, and it was found that the severity of liver cysts increased with increasing medication time. (The combined use of estrogen (estradiol valerate) and adrenocortical hormone (dexamethasone sodium phosphate) can lead to the appearance of liver cysts.
[0027] In some embodiments of the present invention, the amount of estrogen estradiol valerate administered is 3.33 mg / kg, and the administration frequency is twice a week;
[0028] The amount of adrenocortical hormone dexamethasone sodium phosphate is 0.5 mg / kg, and the administration frequency is 2 times a week.
[0029] Among them, estrogen (estradiol valerate) is administered by gavage, and adrenocortical hormone (dexamethasone sodium phosphate) is administered by subcutaneous injection.
[0030] Beneficial effects of the present invention:
[0031] The present invention finds through experiments that an animal model of liver cysts can be obtained by administering streptozotocin to experimental animals, and also finds that administering estrogen (estradiol valerate) and adrenocortical hormone (dexamethasone sodium phosphate) alone or in combination after administering streptozotocin can accelerate the acquisition of the animal model of liver cysts, thus providing an animal model for studying liver cysts and laying a clinical foundation for the diagnosis and treatment of liver cysts in clinic. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Abdominal distension (left) and diffuse liver cysts (right) in a gerbil some time after intraperitoneal injection of streptozotocin.
[0033] Figure 2 These are the microscopic manifestations of the liver after dissection of the gerbil following intracavitary injection of streptozotocin. The left image is a 25× magnification image, and the right image is a 100× magnification image.
[0034] Figure 3Reticular fiber staining (A is reticular staining 400×) and immunohistochemistry (B is AFP; C is CD34; D is CK19; E is HEP; F is P53) of the liver of the long-clawed gerbil after intraperitoneal injection of streptozotocin; G is the gross view of the liver.
[0035] Figure 4 The figures show the extent of liver cysts in the blank group and the model group (single intraperitoneal injection of streptozotocin 150 mg / kg) of long-clawed gerbils after 16.5 months of feeding; A, C, E, G, and I are the control groups; B, D, F, H, and J are the model groups.
[0036] Figure 5 These are liver pathological sections of the blank group (right) and model group (left) gerbils after 16.5 months of feeding.
[0037] Figure 6 The electron micrographs of the livers of the blank group and the model group of long-clawed gerbils after 16.5 months of feeding at different magnifications; AD is 15000×, E and F are 50000×; A, C, E, and F are model groups, and B and D are blank groups.
[0038] Figure 7 The liver conditions of gerbils were observed at different time points after intraperitoneal injection of STZ; A was sampled 4 months later, showing the liver condition of gerbils; B was sampled 7 months later, showing the liver condition of gerbils; C was sampled 8 months later, showing the liver condition of gerbils; D was sampled 9 months later, showing the liver condition of gerbils; E was sampled 10 months later, showing the liver condition of gerbils; F was sampled 12 months later, showing the liver condition of gerbils; G was sampled 16.5 months later, showing the liver condition of gerbils; H was sampled 18-19 months later, showing the liver condition of gerbils.
[0039] Figure 8The samples were taken 24 days, 42 days and 3 months after the administration of estradiol valerate and the liver condition was observed 3 months after the long-clawed gerbil was injected with STZ intraperitoneally. The drugs were administered and the samples were taken 24 days, 42 days and 3 months after the administration to observe the liver condition. Among them, A shows the gross appearance of the liver of the long-clawed gerbil 3 months after the STZ injection, without any drugs, and the samples were taken 24 days later; B shows the gross appearance of the liver of the long-clawed gerbil 3 months after the STZ injection, and the samples were taken 24 days after the administration of estradiol valerate, and the liver condition was observed; C shows the gross appearance of the liver of the long-clawed gerbil 3 months after the STZ injection, and the samples were taken 24 days after the administration of dexamethasone sodium phosphate, and the liver condition was observed; D shows the gross appearance of the liver of the long-clawed gerbil 3 months after the STZ injection, and the samples were taken 24 days after the combined administration of estradiol valerate and dexamethasone sodium phosphate, and the liver condition was observed. E is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and without medication for 42 days; F is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and after medication of estradiol valerate for 42 days; G is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and after medication of dexamethasone sodium phosphate for 42 days; H is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and after combined administration of estradiol valerate + dexamethasone sodium phosphate for 42 days; I is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and after medication of estradiol valerate for 3 months; J is the gross appearance of the liver of a long-clawed gerbil sampled 3 months after STZ injection and after combined administration of estradiol valerate + dexamethasone sodium phosphate.
[0040] Fig. 9 The samples were taken 24 days, 42 days and 3 months after STZ was injected intraperitoneally into the long-clawed gerbils, and the pathological conditions of the liver were observed under a microscope (magnification 100 times). A shows a pathological section of the liver of a long-clawed gerbil 3 months after STZ injection without any medication and sampling 24 days later. B shows a gross view of the liver of a long-clawed gerbil 3 months after STZ injection and sampling 24 days after estradiol valerate was administered. C shows a pathological section of the liver of a long-clawed gerbil 3 months after STZ injection and sampling 24 days after dexamethasone sodium phosphate was administered. D shows a pathological section of the liver of a long-clawed gerbil 3 months after STZ injection and sampling 24 days after the combined administration of estradiol valerate and dexamethasone sodium phosphate. E shows a pathological section of the liver of a long-clawed gerbil 3 months after STZ injection. 3 months after STZ injection, samples were collected without medication for 42 days, and liver pathology sections were obtained; F is a liver pathology section of a long-clawed gerbil sampled 3 months after STZ injection and estradiol valerate was administered for 42 days; G is a liver pathology section of a long-clawed gerbil sampled 3 months after STZ injection and dexamethasone sodium phosphate was administered for 42 days; H is a liver pathology section of a long-clawed gerbil sampled 3 months after STZ injection and estradiol valerate + dexamethasone sodium phosphate were administered for 42 days; I is a liver pathology section of a long-clawed gerbil sampled 3 months after STZ injection and estradiol valerate was administered for 3 months; J is a liver pathology section of a long-clawed gerbil sampled 3 months after STZ injection and estradiol valerate was administered for 3 months.
[0041] Fig.10 The gross liver condition of long-clawed gerbils was examined 3 months after STZ injection and combined administration of estradiol valerate and dexamethasone sodium phosphate.
[0042] Fig.11 The gross liver condition of the gerbils was analyzed 4 months after STZ injection and combined administration of estradiol valerate and dexamethasone sodium phosphate.
[0043] Fig.12 The gross liver condition of long-clawed gerbils was examined 6 months after STZ injection and combined administration of estradiol valerate and dexamethasone sodium phosphate.
[0044] Fig.13 The long-clawed gerbils were injected with STZ and then given estradiol valerate + dexamethasone sodium phosphate. The pathological changes in the liver were observed 3, 4 and 6 months later. AB shows the pathological changes in the liver after 3 months of combined administration; CD shows the pathological changes in the liver after 4 months of combined administration; E shows the pathological changes in the liver after 6 months of combined administration; F shows the pathological changes in the liver after 6 months of STZ injection in long-clawed gerbils. DETAILED DESCRIPTION
[0045] Example 1
[0046] In our previous study, we accidentally found that after a single intraperitoneal injection of streptozotocin 150mg / kg or 200mg / kg, the gerbils developed obvious abdominal distension after being raised for an average of about 20 months. Dissection revealed ascites, enlarged liver, diffuse cysts, and a honeycomb-like cross-section. The cysts varied in size, ranging from about 1mm to more than 2cm. The cysts were scattered throughout the liver or a certain lobe of the liver. The cyst cavity contained clear and transparent liquid, which was colorless or light yellow. Some gerbils had liver cysts like Figure 1 shown.
[0047] Microscopically, the bile ducts are diffusely dilated and lined with columnar or cuboidal epithelium. Large cysts may be flat epithelium with no cell atypia. The cysts are surrounded by fibrous tissue proliferation with lymphocyte infiltration. Figure 2 ).
[0048] The liver is grossly Figure 3 As shown in G, reticular fiber staining showed connective tissue proliferation around some hepatocytes ( Figure 3 A); Immunohistochemistry showed: hepatocyte AFP (-), hepatic sinusoid AFP (+), bile duct AFP (-) ( Figure 3 B); hepatocyte CD34(-), hepatic sinusoid CD34(+), bile duct CD34(-)( Figure 3 C); hepatocyte ck19(-), hepatic sinusoid ck19(-), bile duct ck1 9(+)( Figure 3 D); Hepatocyte HEP(+), bile duct HEP(-)( Figure 3 E); hepatocyte P53(-), hepatic sinusoid P53(+), bile duct P53(-)( Figure 3 F).
[0049] In order to clarify whether intraperitoneal injection of STZ can cause liver cysts in long-clawed gerbils, we repeated the experiment and divided the mice into two groups: a blank group (no STZ injection, intraperitoneal injection of the same dose of STZ-dissolving buffer) and a model group (intraperitoneal injection of STZ 150 mg / kg), with 10 mice in each group. After intraperitoneal injection of STZ, the model group developed liver cysts of varying degrees at 16.5 months. Figure 4 -A, C, E, G, I), and no abnormality was found in the blank group ( Figure 4 -B, D, F, H, J), proving that STZ can indeed cause liver cysts in long-clawed gerbils.
[0050] Select Figure 4 A model group and Figure 4 The blank group of B was subjected to pathological sectioning and electron microscope photography, where:
[0051] The pathological sections are as follows: Compared with the blank group, 16.5 months after intraperitoneal injection of streptozotocin, the model group showed diffuse dilatation of the intrahepatic and extrahepatic bile ducts under the microscope, with columnar or cuboidal epithelium lining the inner wall, flat epithelium in the large cysts, no cell atypia, and hyperplasia of fibrous tissue around the cysts with lymphocyte infiltration ( Figure 5 ).
[0052] Electron microscopic image description: Under electron microscopy, compared with the blank group, the villi between adjacent bile duct cells in the model group became shorter and more messy ( Figure 6 ).
[0053] Example 2
[0054] In order to explore the time of appearance of liver cysts after intraperitoneal injection of STZ in long-clawed gerbils, the following experiment was designed: After intraperitoneal injection of STZ (150 mg / kg), samples were taken at different time points to observe the liver condition of gerbils. Samples were taken at 4 months, 7 months, 8 months, 9 months, 12 months, 16.5 months, and 19 months after intraperitoneal injection of STZ. The gross photos are shown in Figure 7 .
[0055] The results showed that intraperitoneal injection of STZ in gerbils can cause liver cysts in gerbils, and STZ can be used as an animal model for studying liver cysts.
[0056] Example 3
[0057] The above examples show that STZ can cause liver cysts in long-clawed gerbils and can be used as an animal model for studying liver cysts. However, the modeling time is too long and it is inconvenient to use. After consulting the literature, it was found that estrogen and adrenocortical hormones can promote the occurrence of cysts. We want to know whether the two drugs can accelerate the occurrence of cysts after long-clawed gerbils are injected with STZ, and designed relevant experiments (estradiol valerate was selected as estrogen and dexamethasone sodium phosphate was selected as adrenocortical hormone).
[0058] 1. Administer medication 3 months after STZ injection
[0059] Three months after a single intraperitoneal injection of STZ (150 mg / kg) in long-clawed gerbils, drug administration began.
[0060] Among them, blank group: no medication;
[0061] Estradiol valerate group: estradiol valerate (3.33 mg / kg) was administered orally twice a week;
[0062] Dexamethasone sodium phosphate group: dexamethasone sodium phosphate (0.5 mg / kg) was injected subcutaneously twice a week;
[0063] Dexamethasone sodium phosphate + estradiol valerate combined administration group: estradiol valerate (3.33 mg / kg) was administered orally and dexamethasone sodium phosphate (0.5 mg / kg) was injected subcutaneously twice a week;
[0064] 24 days, 42 days and 3 months after the start of drug administration, samples were taken to observe whether liver cysts appeared, and pathological sections were performed. The results showed that the degree of liver cysts at different time points was different. As the time after drug administration increased, the degree of cysts also increased. The combined administration of dexamethasone sodium phosphate + estradiol valerate can lead to the appearance of liver cysts ( Figure 8 ). Pathological section results showed Fig. 9 shown.
[0065] 2. After STZ injection, administer the drug directly
[0066] After STZ injection, the long-clawed gerbils were given direct administration, and the dexamethasone sodium phosphate + estradiol valerate combined administration group: estradiol valerate (3.33 mg / kg) was administered orally, and dexamethasone sodium phosphate (0.5 mg / kg) was injected subcutaneously, and the combined administration was given twice a week; samples were taken 3 months, 4 months, and 6 months after direct administration to observe whether liver cysts appeared. The results showed that long-clawed gerbils could develop a certain degree of liver cysts at different time points ( Figures 10-12 ), pathological results are shown in Fig.13 .
[0067] In summary, the experiment found that the administration of streptozotocin to experimental animals can obtain an animal model of liver cysts. It was also found that the administration of estrogen and corticosteroids alone or in combination after the administration of streptozotocin can accelerate the acquisition of the animal model of liver cysts, which provides an animal model for the study of liver cysts and lays a clinical foundation for the diagnosis and treatment of liver cysts in clinical practice.
Claims
1. A method for constructing an animal model of liver cysts. Features The method comprises the following steps: administering streptozotocin to experimental animals, and then feeding the experimental animals until liver cysts grow out of the experimental animals, so as to obtain a liver cyst animal model.
2. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that The route of administration of streptozotocin is intraperitoneal injection.
3. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that The dose of streptozotocin administered is 150 mg / kg-200 mg / kg.
4. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that The number of times streptozotocin was administered was 1 time.
5. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that The timing of administration of streptozotocin is: Administer to experimental animals of any age.
6. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that The experimental animals were long-clawed gerbils.
7. The method for constructing an animal model of liver cysts according to claim 1, It is characterized in that After the experimental animals are administered with streptozotocin, at least one of estrogen and adrenocortical hormone is administered.
8. The method for constructing an animal model of liver cysts according to claim 7, It is characterized in that After the administration of streptozotocin, at least one of estrogen and adrenocortical hormone is administered again at an interval of 3 months.
9. The method for constructing an animal model of liver cysts according to claim 8, It is characterized in that When both estrogen and corticosteroids are administered, the two drugs are administered in combination.
10. The method for constructing an animal model of liver cysts according to claim 8, It is characterized in that The amount of estrogen administered was 3.33 mg / kg, and the frequency of administration was 2 times / week; The amount of adrenocortical hormone administered was 0.5 mg / kg, and the administration frequency was 2 times / week.
Citation Information
Patent Citations
Application of streptozotocin in preparing medicine for causing hypogonadism
CN108295081A
Method of simulating liver abscess with rupture into abdomen
RU1774371C
